Note 7 - Commitments and Contingencies (Details Textual) - USD ($)				1 Months Ended		3 Months Ended			5 Months Ended	9 Months Ended		12 Months Ended
	May 02, 2025	Jun. 30, 2024	Sep. 30, 2022	Jun. 30, 2024	Jul. 31, 2018	Sep. 30, 2025	Sep. 30, 2024	Mar. 31, 2017	Jun. 06, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Dec. 31, 2009	Apr. 25, 2025	Feb. 17, 2025	Nov. 11, 2024	Mar. 31, 2023	Mar. 03, 2021
Costs and Expenses						$ 3,345,913	$ 4,323,438			$ 11,996,987	$ 16,838,438
License Agreement Terms [Member]
Costs and Expenses										155,000	50,000
Contract Payments Incurred and Paid										525,000
License Agreement Milestone Payment																		$ 6,150,000
National Institute of Health [Member]
Royalty on Sales, Percentage													1.00%
Royalty Term (Year)													21 years
Royalty Payment, Annual Minimum													$ 20,000
Payment for Contingent Consideration Liability, Operating Activities								$ 240,000
Contingent Payments Annual Increase								$ 20,000
Other Commitment						400,000				400,000		$ 380,000
Research Agreement [Member] | MD Anderson [Member]
Long Term Contract, Estimated Cost			$ 2,900,000		$ 2,000,000				$ 2,900,000			$ 2,760,000
Long Term Contract, Quarterly Budget Allocated				$ 165,000					$ 240,000
Costs and Expenses						165,701
Contract Payments Incurred and Paid						2,100,000
License Agreement [Member] | NYU [Member]
Contract Payments Incurred and Paid										5,000
Licensing Fee, Amount														$ 5,000
Licensing Fee, Amount, Annual, First Two Years														35,000
Licensing Fee, Amount, Annual, Third Year														25,000
Licensing Fee, Amount, Annual, Fourth and Subsequent Years														50,000
Milestone Payment														$ 400,000
License Agreement [Member] | NYU [Member] | Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent														1.00%
License Agreement [Member] | NYU [Member] | Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent														2.00%
License Agreement [Member] | University Of Michigan [Member]
Costs and Expenses						0
Licensing Fee, Amount																$ 30,000
Minimum Annual Royalty Fixed Amount, First Two Years																15,000
Minimum Annual Royalty Fixed Amount, Third Year and Thereafter																$ 30,000
License Agreement [Member] | University Of Michigan [Member] | Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent																1.00%
Share of Non-Royalty Sublicense Income, Percent																10.00%
License Agreement [Member] | University Of Michigan [Member] | Maximum [Member]
Contract Payments Incurred and Paid						30,000
Royalty Percent, Licensed Technology Covered by Patent																3.00%
Share of Non-Royalty Sublicense Income, Percent																40.00%
Commercial Sales Milestone, Additional FDA Regulatory Approval																$ 350,000
License Agreement [Member] | University of Pittsburgh [Member]
Licensing Fee, Amount															$ 10,000
Annual Maintenance Fee, First Three Years, Amount															65,000
Annual Maintenance Fee, After Year Three, Amount															120,000
License Agreement [Member] | University of Pittsburgh [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Costs and Expenses						0
Contract Payments Incurred and Paid						$ 10,000
Milestone Payment															$ 4,825,000
Share of Non-Royalty Sublicense Income, Percent															20.00%
Annual Royalty Payment Per Year, Minimum															$ 250,000
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent															1.50%
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent															3.00%
License Agreement [Member] | UTHealth Houston [Member]
Contract Payments Incurred and Paid										10,000
Licensing Fee, Amount	$ 10,000
Annual Royalty Payment Per Year, Minimum	25,000
Licensing Fee, Amount, Staggered Upfront	40,000
Licensing Fee, Amount, Management	3,000
Clinical and Regulatory Expense	$ 360,000
License Agreement [Member] | UTHealth Houston [Member] | Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent	0.10%
License Agreement [Member] | UTHealth Houston [Member] | Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent	0.25%
Development and Manufacturing of GMP Grade Materials [Member]
Costs and Expenses										$ 0	$ 0
Development Services Agreement, Expected Total Project Cost																	$ 4,500,000
Contract Payments, Returned to Company		$ 1,300,000